Seeking Alpha

Joe Springer's  Instablog

Joe Springer
Send Message
It is very hard or impossible to time the broad market consistently — there are no famous investors that got rich by consistently knowing what the broad market would do next. This only makes sense, as there are just too many variables in the broad market. But there are many famous investors who... More
My company:
The Wall Street Exclusive
My blog:
The Wall Street Exclusive
View Joe Springer's Instablogs on:
  • Tonix On Sale For Limited Time, Upside Intact

    I'm doing a quick write-up, and results were not perfect, but BESTFIT reported across the board improvements in symptoms and did very well in safety and side effects.

    They will begin AtEase with TNX-102 SL in PTSD and will meet with the FDA within roughly 75 days for FM, but they are cautiously expecting to move forward with the approval process.

    Trading just above cash the point is the entire upside is still intact..

    Tags: TNXP
    Sep 29 9:20 AM | Link | 14 Comments
  • Fire Away

    Lots of comments and questions on Tonix (NASDAQ:TNXP) in various places, if you have a question (and have looked and still don't know, not dying to repeat ourselves) you can ask here.

    Pre-emptively - YES, bullish as ever.

    Tags: TNXP
    Sep 14 12:21 PM | Link | 135 Comments
  • What Success Should Look Like For TNX-102 SL

    Here's a linkfest of the trials for Tonix Pharmaceuticals' (NASDAQ:TNXP) TNX-102 and the three approved drugs in FM. The mean baseline of patient pain at the beginning of the trial is listed after each, the percentage of most intense pain that number represents is calculated to compare the trials to each other:

    • TNX-102 2a (2.2 on 0-6 scale with 6 most intense) 46%
    • Lyrica (7 on 0-10 scale with 10 most intense) 73%
    • Lyrica 2 (7.1 on 0-10 scale with 10 most intense) 74%
    • Cymbalta (6.525 on 0-10 scale with 10 most intense) 68%
    • Cymbalta 2 (6.6 on 0-10 scale with 10 most intense) 69%
    • Cymbalta 3 (6.5 on 0-10 scale with 10 most intense) 68%
    • Savella (logarithmic scale and not provided)
    • Savella 2 (71.2 on 0-100 scale with 100 most intense) 71%

    Tonix' 2a trial was small, so the fact that it got statistical significance in pain, tenderness, and depression vs placebo is notable. It is also notable that the most important measure (pain) started from a not very elevated level in the first place.

    Have a look at the amount of improvements and the changes over time in the trials for the approved drugs. Lyrica, for example, was typical. Something like this should be what approval looks like for TNX-102 SL:

    (click to enlarge)

    Tags: TNXP
    Sep 02 5:44 AM | Link | 32 Comments
Full index of posts »
Latest Followers


More »

Latest Comments

Most Commented
  1. Fire Away ( Comments)
  2. I Am You See ( Comments)
  3. What Is Tonix Worth? ( Comments)
  4. Hooked On Tonix ( Comments)
  5. Seattle Super-Tonix ( Comments)
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.